Renalytix (Reg S) (RENX)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

8.40p
   
  • Change Today:
      0.15p
  • 52 Week High: 12.50p
  • 52 Week Low: 5.62p
  • Currency: UK Pounds
  • Shares Issued: 437.02m
  • Volume: 973,312
  • Market Cap: £36.71m
  • RiskGrade: 348

Latest ShareCast News

Renalytix shares more than double after striking US diagnostics partnership

By Iain Gilbert

Date: Monday 15 Sep 2025

(Sharecast News) - Medical diagnostics firm Renalytix said on Monday that it has struck a definitive agreement with Tempus AI to accelerate the adoption of its kidneyintelX.dkd test to support early-stage risk assessment in chronic kidney disease, slow progression, and improve patient outcomes.

Renalytix enters new collaboration with NYKHM

By Josh White

Date: Tuesday 03 Jun 2025

(Sharecast News) - Renalytix announced a new collaboration with New York Kidney & Hypertension Medicine (NYKHM) on Tuesday, aimed at expanding access to its FDA-approved kidneyintelX.dkd test across underserved communities in the Greater New York area.

Renalytix Q3 revenues up 20pc

By Iain Gilbert

Date: Thursday 10 Apr 2025

(Sharecast News) - Precision medicine business Renalytix said on Thursday that Q3 trading was in line with expectations, delivering 20% quarter-on-quarter revenue growth as it reached "the key milestone" of processing over 1,000 billable tests within the quarter for the first time.

Renalytix terminates formal sale process 20-Aug-2024 ShareCast
Renalytix test gets US Medicare coverage determi... 14-Jun-2024 ShareCast
Renalytix surges on takeover approach 04-Mar-2024 ShareCast
Renalytix shares jump on draft US Medicare cover... 09-Feb-2024 ShareCast
Renalytix kidney test claims allowed by US Paten... 06-Oct-2023 ShareCast
Renalytix gets KidneyIntelX included in major cl... 21-Aug-2023 ShareCast
Renalytix launches kidney disease test in Arabia... 21-Jul-2023 ShareCast
Renalytix test gets US FDA marketing authorisation 30-Jun-2023 ShareCast
Renalytix secures expanded coverage in Washingto... 22-May-2023 ShareCast
Renalytix reports positive study on clinical val... 19-Apr-2023 ShareCast
Renalytix rises on publication of positive evide... 29-Nov-2022 ShareCast
Renalytix reports positive outcomes from Mount S... 10-Jun-2022 ShareCast
Renalytix completes financing to support its gro... 08-Apr-2022 ShareCast
Revenue rises, losses widen in first half at Ren... 31-Mar-2022 ShareCast
Renalytix hits patient milestone for kidney and ... 29-Mar-2022 ShareCast
Renalytix launches new US provider access portal 09-Mar-2022 ShareCast
Renalytix presents new clinical data on KidneyIn... 24-Feb-2022 ShareCast
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

RENX Market Data

Currency UK Pounds
Share Price 8.40p
Change Today 0.15p
% Change 1.82 %
52 Week High 12.50p
52 Week Low 5.62p
Volume 973,312
Shares Issued 437.02m
Market Cap £36.71m
RiskGrade 348

RENX Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend Not Available
Income Not Available
Growth Not Available

RENX Dividends

No dividends found

Trades for 24-Oct-2025

Time Volume / Share Price
16:23 21,568 @ 8.37p
15:31 7,002 @ 8.44p
15:30 5,831 @ 8.42p
15:25 7,000 @ 8.37p
15:23 5,518 @ 8.42p

RENX Key Personnel

CEO James Renwick McCullough

Top of Page